Medicinal Chemistry International: List Of drugs 2014 FDA

List Of drugs 2014 FDA

JANUARY

ENTRY1

Farxiga (dapagliflozin) Tablets

Company: Bristol-Myers Squibb Company and AstraZeneca
Date of Approval: January 8, 2014
Treatment for: Diabetes Type 2

Farxiga (dapagliflozin) is a selective sodium-glucose cotransporter-2 inhibitor for the treatment of adults with type 2 diabetes mellitus.

LINK FOR SYNTHESIS
CLICK HEREhttp://newdrugapprovals.wordpress.com/2013/12/18/dapagliflozin-sees-light/

ENTRY 2

TASIMELTION…FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals

Generic Name: tasimelteon
Date of Approval: January 31, 2014
Company: Vanda Pharmaceuticals, Inc.

http://newdrugapprovals.org/2014/02/01/tasimeltion-fda-approves-hetlioz-first-treatment-for-non-24-hour-sleep-wake-disorder-in-blind-individuals/

FEBRUARY

ENTRY3
FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA
Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).
Company: BioMarin Pharmaceutical Inc.
Date of FDA Approval: February 14, 2014
Treatment for: Mucopolysaccharidosis Type IVA
LINK
http://newdrugapprovals.org/2014/02/17/fda-approves-vimizim-to-treat-mucopolysaccharidosis-type-iva/

ENTRY 4
Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014

Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain,

Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014

2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid

cas 53-86-1

http://newdrugapprovals.org/2014/02/27/tivorbex-indomethacin-iroko-pharmaceuticals-for-the-treatment-of-acute-pain/

ENTRY5

Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014

The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has recommended AstraZeneca and Bristol-Myers Squibb’s (BMS) investigational medicine metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy (LD).